SCYNEXIS INC Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by SCYNEXIS, Inc. on September 10, 2026, reporting events occurring on September 9 and September 10, 2026. The filing addresses significant changes in the Company's executive leadership, specifically the departure of the Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and personnel changes.
Material Changes
- Departure of CFO: Ivor Macleod, CPA, MBA, retired as Chief Financial Officer, principal financial officer, and principal accounting officer effective September 9, 2026. He will remain with the Company until October 9, 2026, to facilitate a transition.
- Appointment of New CFO: Sanjay Subramanian, MBA, was appointed as Chief Financial Officer, principal financial officer, and principal accounting officer effective September 9, 2026.
Compensation, Outlook, and Risks
The filing details the employment agreement for the new CFO, Sanjay Subramanian, effective September 9, 2026:
- Base Salary: $500,000 annually.
- Sign-on Bonus: One-time payment of $20,000.
- Performance Bonus: Discretionary annual bonus of up to 40% of base salary.
- Equity: Stock option to purchase 100,000 shares of common stock at the closing price on the grant date, vesting over four years.
- Severance Provisions:
- Standard termination (without cause) or resignation for good reason: 9 months base salary, 9 months accelerated equity vesting, and up to 9 months COBRA benefits.
- Termination within 12 months of a change of control: 18 months base salary, full accelerated equity vesting, and up to 18 months COBRA benefits.
Mr. Subramanian brings over 20 years of experience in biopharmaceutical finance, having previously served as CFO at Inozyme Pharma, Inc. and Ocugen, Inc. The filing notes no family relationships or undisclosed material interests.
Investor Verification Checklist
- Verify the transition timeline and the extent of Mr. Macleod's remaining involvement through October 9, 2026.
- Confirm the grant date and exercise price for Mr. Subramanian's 100,000 stock options.
- Review the specific definitions of "just cause" and "good reason" in the employment agreement to understand severance triggers.
- Assess the impact of the new CFO's background on the Company's capital markets and business development strategy.